Search
sugemalimab
Indications:
- non-small cell lung cancer (NSCLC)
Dosage:
- 1200 mg intravenously every 3 weeks for up to 24 months
Adverse effects:
- pneumonitis
Mechanism of action:
- PD-L1 inhibitor
Clinical trials:
- GEMSTONE-302: sugemalimab in combination with platinum-based chemotherapy as 1st line treatment of NSCLC improves progression-free survival at 18 months relative to platinum-based chemotherapy alone [1]
Interactions
drug adverse effects of checkpoint inhibitor(s)
General
antineoplastic monoclonal antibody
checkpoint inhibitor; immune checkpoint inhibitor; PD-1/PD-L1 inhibitor
References
- Bassett M
Sugemalimab Boosts Outcomes in NSCLC.
Results from two trials showed significantly prolonged PFS with the
anti-PD-L1 antibody.
MedPage Today January 19, 2022
https://www.medpagetoday.com/hematologyoncology/lungcancer/96754
- Zhou C, Wang Z, Sun Y et al
Sugemalimab versus placebo, in combination with platinum-based chemotherapy,
as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302):
interim and final analyses of a double-blind, randomised, phase 3 clinical trial.
Lancet Oncology.2022 Jan 14;S1470-2045(21)00650-1
PMID: 35038432
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00650-1/fulltext